Evidence map›Paper›PMID 24621646›Full record

SynthesisPloS one2014

Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis.

Yazhou He, Yuanchuan Zhang, Chengwu Jin, Xiangbing Deng, Mingtian Wei, Qingbin Wu, Tinghan Yang, Yanhong Zhou, Ziqiang Wang

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Analysis ofBiomedical reports · 2016
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yazhou HeDepartment of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China; West China School of Medicine/West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
Yuanchuan ZhangDepartment of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
Chengwu JinDepartment of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
Xiangbing DengDepartment of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
Mingtian WeiDepartment of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
Qingbin WuWest China School of Medicine/West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
Tinghan YangDepartment of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
Yanhong ZhouDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu,Sichuan Province, P.R China.
Ziqiang WangDepartment of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
West China Hospital of Sichuan University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAssociation between the single nucleotide polymorphism rs3218536 (known as Arg188His) located in the X-ray repair cross complementing group 2 (XRCC2) gene and cancer susceptibility has been widely investigated. However, results thus far have remained controversial. A meta-analysis was performed to identify the impact of this polymorphism on cancer susceptibility.

methodsPubMed and Embase databases were searched systematically until September 7, 2013 to obtain all the records evaluating the association between the XRCC2 Arg188His polymorphism and the risk of all types of cancers. We used the odds ratio (OR) as measure of effect, and pooled the data in a Mantel-Haenszel weighed random-effects meta-analysis to provide a summary estimate of the impact of this polymorphism on breast cancer, ovarian cancer and other cancers. All the analyses were carried out in STATA 12.0.

resultsWith 30868 cases and 38656 controls, a total of 45 case-control studies from 26 publications were eventually included in our meta-analysis. No significant association was observed between the XRCC2 Arg188His polymorphism and breast cancer susceptibility (dominant model: OR = 0.94, 95%CI = 0.86-1.04, P = 0.232). However, a significant impact of this polymorphism was detected on decreased ovarian cancer risk (dominant model: OR = 0.83, 95%CI = 0.73-0.95, P = 0.007). In addition, we found this polymorphism was associated with increased upper aerodigestive tract (UADT) cancer susceptibility (dominant model: OR = 1.51, 95%CI = 1.04-2.20, P = 0.032).

conclusionThe Arg188His polymorphism might play different roles in carcinogenesis of various cancer types. Current evidence did not suggest that this polymorphism was directly associated with breast cancer susceptibility. However, this polymorphism might contribute to decreased gynecological cancer risk and increased UADT cancer risk. More preclinical and epidemiological studies were still imperative for further evaluation.

Indexed as

Polymorphism, Single NucleotideDNA-Binding ProteinsGenetic Predisposition to DiseaseHumansNeoplasmsDNA-Binding ProteinsXRCC2 protein, human

Identifiers

PMID24621646
PMCPMC3951328
OpenAlexW1979983370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.